Lynx Dx
Mark Willig is an accomplished executive with extensive experience in leadership roles across various companies in the life sciences sector. As of July 2023, Mark serves as President, Chief Executive Officer, and Member of the Board of Directors at Key Proteo, Inc. Additionally, Mark holds advisory and board positions at LynxDx and AggioSergeant International. Previous leadership roles include President and CEO at Alveo Technologies and Chief Commercial Officer at both Curative and CardioDx. Mark founded Blue Ocean Consulting, LLC - Life Sciences and has held significant positions at Agendia, Exiqon A/S, and Thermo Fisher Scientific. Mark's educational background includes a Bachelor of Science in Communications from the University of Missouri-Columbia.
This person is not in the org chart
This person is not in any teams
Lynx Dx
MyProstateScore 2.0 is a personalized, comprehensive, data-driven prostate cancer screening solution designed to predict the presence of clinically significant prostate cancer (Grade Group ≥2 or Gleason score ≥7). The algorithm is specifically optimized for unrivaled accuracy for both previously negative biopsy and biopsy naïve patients.